Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Evotec AG and Bayer AG’s Bayer Pharma AG Enter Into Multi-Target Alliance to Fight Endometriosis


Monday, 1 Oct 2012 04:43am EDT 

Evotec AG (Evotec) announced that Evotec and Bayer AG’s Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Both parties will contribute drug targets and technology infrastructures and will share the responsibility for early research and pre-clinical characterization of potential clinical candidates in the disease area of endometriosis. Bayer will be responsible for any subsequent clinical development and commercialization. Evotec will receive EUR 12 million as an upfront payment. Evotec may also receive additional pre-clinical, clinical and sales milestones of potentially up to approximately EUR 580 million, plus potential royalties of up to low double digit% of net sales, depending on which party brought the compound to the collaboration and the development and approval of potential drug candidates. 

Company Quote

95.41
-2.28 -2.33%
15 Aug 2014